Blog

Emma M. Groarke: We found that there was more than 40% cumulative incidence of venous and arterial thrombosis in patients with VEXAS

Photo from Emma M. Groarke/X

Feb 8, 2024, 14:58

Emma M. Groarke: We found that there was more than 40% cumulative incidence of venous and arterial thrombosis in patients with VEXAS

Emma M. Groarke, Hematologist at the National Institutes of Health (NIH), shared a post on X/Twitter:

“Very excited to share our NIH-Mayo Clinic collaboration just published in Blood Journal focused on the thrombotic manifestations occurring in VEXAS.

We found that there was >40% cumulative incidence of venous and arterial thrombosis in patients with VEXAS; many events occurred at initial disease presentation. Cardiac or pulmonary involvement appear to confer increased risk.

Thrombosis seems to be driven by inflammation. Patients almost ubiquitously had high FVIII levels and many had high VWD antigen and activity.”

Source: Emma M. Groarke/X

Blood Journal cancer Emma M. Groarke Mayo Clinic National Institutes of Health (NIH). NIH OncoDaily Oncology venous and arterial thrombosis Vexas VWD antigen

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage